Anavex Life Sciences Corp.AVXLNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P5
Near historical low
vs 5Y Ago
-8.3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -40.11% |
| Q3 2025 | -21.11% |
| Q2 2025 | 71.69% |
| Q1 2025 | -16.69% |
| Q4 2024 | 13.12% |
| Q3 2024 | -0.39% |
| Q2 2024 | -3.56% |
| Q1 2024 | 7.46% |
| Q4 2023 | 3.95% |
| Q3 2023 | -20.21% |
| Q2 2023 | 12.66% |
| Q1 2023 | -13.08% |
| Q4 2022 | -15.00% |
| Q3 2022 | 22.51% |
| Q2 2022 | 9.27% |
| Q1 2022 | -4.95% |
| Q4 2021 | 6.53% |
| Q3 2021 | 18.28% |
| Q2 2021 | 8.97% |
| Q1 2021 | 51.89% |
| Q4 2020 | 4.83% |
| Q3 2020 | 1.55% |
| Q2 2020 | -19.69% |
| Q1 2020 | 27.23% |
| Q4 2019 | -17.32% |
| Q3 2019 | 17.76% |
| Q2 2019 | -32.63% |
| Q1 2019 | 17.03% |
| Q4 2018 | 18.88% |
| Q3 2018 | -8.57% |
| Q2 2018 | 8.79% |
| Q1 2018 | 6.56% |
| Q4 2017 | 2.70% |
| Q3 2017 | -3.13% |
| Q2 2017 | 25.90% |
| Q1 2017 | -0.90% |
| Q4 2016 | -49.81% |
| Q3 2016 | 97.73% |
| Q2 2016 | 4.15% |
| Q1 2016 | -67.65% |